Oral gildeuretinol acetate did not meet the primary endpoint of geographic atrophy lesion growth rate in a phase 3 study, according to a press release from Alkeus Pharmaceuticals.
The SAGA study investigated ALK-001, a specialized form of deuterated vitamin A that can reduce dimerization of vitamin A without affecting vision, according to the release.
The study enrolled 198 patients with geographic atrophy (GA) secondary to age-related macular degeneration and explored the growth rate of GA lesions from baseline to 24 months as the primary efficacy endpoint. Change in low luminance visual